What is the ‘real‐world’ experience with fixed‐ratio combination therapy (insulin + GLP ‐1 receptor agonist) in routine clinical practice? Take‐home messages for clinicians regarding key outcomes

Documents similaires

• iGlarLixi : A titrateable fixed‐ratio combination of basal insulin + GLP‐1 receptor agonist—An effective type 2 diabetes treatment option in China
  par: Miao Yu
  Publié: (2025)
• Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist
  par: Luděk Horváth, et autres
  Publié: (2025)
• An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes
  par: Geremia B. Bolli, et autres
  Publié: (2025)
• Short‐term outcomes of switching from GLP ‐1 receptor agonists to tirzepatide in type 2 diabetes: A retrospective, observational study in clinical practice
  par: Mari Matsushiro, et autres
  Publié: (2025)
• Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
  par: Hans Johnson, et autres
  Publié: (2025)